Study details
Enrolling now
Olanzapine for Cancer Appetite Loss
OHSU Knight Cancer Institute
NCT IDNCT05705492ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
66
Study length
about 1.5 years
Ages
18+
Locations
1 site in OR
About this study
This trial is testing if olanzapine helps manage appetite loss in people with advanced cancers like esophageal, lung, or colon cancer. Olanzapine is a medication that may stimulate appetite and improve quality of life.
Based on ClinicalTrials.gov records.
What participants do
- 1.Questionnaire Administration
- 2.Take Olanzapine
- 3.Take Placebo Administration
PhasePhase 2
DrugOlanzapine
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
olanzapine
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Change in Weight, Incidence of adverse events, Patient Reported Quality of Life, Patient Reported Symptoms, Physical Function, Proportion of patients with ≥1 unplanned hospitalization
Body systems
Oncology